Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024
GlobeNewswire
*- Beneficial clinical responses observed with EO2463 monotherapy already at 6 weeks and complete response rate of 78% in..